2024-04-11 08:55:34 ET
More on Regeneron Pharmaceuticals
- Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate
- Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript)
- Regeneron Pharmaceuticals, Inc. (REGN) Barclays 26th Annual Global Healthcare Conference (Transcript)
- Sanofi and Regeneron’s Dupixent set for large gains with likely COPD approval
- FDA declines to approve Regeneron lymphoma drug odronextamab
Read the full article on Seeking Alpha
For further details see:
DOJ files complaint against Regeneron over Eylea Medicare pricing